Lee Hsin-Pei, Tsung Ta-Hsin, Tsai Yu-Chien, Chen Yi-Hao, Lu Da-Wen
Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Department of Ophthalmology, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan.
Biomedicines. 2024 Sep 3;12(9):2000. doi: 10.3390/biomedicines12092000.
Glaucoma is identified by the loss of retinal ganglion cells (RGCs). The primary approach to managing glaucoma is to control intraocular pressure (IOP). Lately, there has been an increasing focus on neuroprotective therapies for glaucoma because of the limited effectiveness of standard methods in reducing IOP and preventing ongoing vision deterioration in certain glaucoma patients. Various drug-based techniques with neuroprotective properties have demonstrated the ability to decrease the mortality of retinal ganglion cells. This study will analyze the currently recommended drug-based techniques for neuroprotection in the prospective treatment of glaucoma.
青光眼是由视网膜神经节细胞（RGCs）的丧失所确定的。治疗青光眼的主要方法是控制眼压（IOP）。最近，由于标准方法在降低眼压和预防某些青光眼患者持续视力恶化方面效果有限，对青光眼神经保护疗法的关注日益增加。各种具有神经保护特性的基于药物的技术已证明有能力降低视网膜神经节细胞的死亡率。本研究将分析目前推荐的用于青光眼前瞻性治疗的基于药物的神经保护技术。
